Vol 7, No 3 (2022)
Letter to the Editor
Published online: 2022-09-07

open access

Page views 4056
Article views/downloads 325
Get Citation

Connect on Social Media

Connect on Social Media

Intranasal vaccines: a panacea to vaccine hesitancy?

Moyinoluwa Joshua Oladoye12
Medical Research Journal 2022;7(3):274-275.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Freeman D, Lambe S, Yu LM, et al. Injection fears and COVID-19 vaccine hesitancy. Psychol Med. 2021 [Epub ahead of print]: 1–11.
  2. Hassan AO, Shrihari S, Gorman MJ, et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021; 36(4): 109452.
  3. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998; 338(20): 1405–1412.
  4. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004; 350(9): 896–903.
  5. van der Ley PA, Zariri A, van Riet E, et al. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. Front Immunol. 2021; 12: 781280.